The Arab Republic of Egypt, Cairo – 22^nd July, 2019: Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, signed a three-way agreement with Egy Drug Company and Poly Pharm to effectively regulate commercial ties and ensure access of innovative drugs in Egypt. The agreement also aims at diversifying Boehringer Ingelheim’s distributors base locally.

In addition, the new partnership will provide access to Boehringer Ingelheim’s full range of therapies, with the underlying objective to reinforce its leadership position across Egypt, whilst highlighting its keen interest to continue investing in the local market and expanding its network of distributors to boost cooperation levels between the public and private sectors.

Boehringer Ingelheim’s success story in Egypt began over 60 years ago, during which the company has provided key medical innovations that cover a number of disease areas including type 2 diabetes, hypertension, respiratory as well as stroke.

The agreement was signed by Abo El Fotooh El Tawil, Chairman of Egy Drug Company, and Yasser Farghali, General Manager and Head of Human Pharmaceuticals at Boehringer Ingelheim Egypt.

Abo El Fotooh El Tawil, Chairman of Egy Drug Company said, “We continue to collaborate with major multinational pharmaceutical companies in an effort to securing patients’ medical needs while also working towards bridging the gap of drug supply. Our agreement with Boehringer Ingelheim will facilitate access to essential medications through Egy Drug Company’s wide and extensive distribution network across Egypt.”

“We are pleased to sign a partnership agreement with a globally recognized pharmaceutical giant that places medical research at the core of everything it does. This will provide the Egyptian market with the latest innovations that have achieved major medical breakthroughs, and we look forward to introducing these innovations that span multiple areas,” added El Tawil.

Egy Drug Company owns a vast network that includes 58 branches focused on driving distribution activities directly with pharmacies across the entire Egyptian Republic, in addition to operating 28 consumer facing pharmacies throughout the country and a robust logistics fleet that is operational 24/7.

Yasser Farghali, Boehringer Ingelheim’s General Manager and Head of Human Pharmaceuticals in Egypt said, “We are proud to collaborate with Egy Drug Company, which has significant experience in the local market, and routinely monitors its key medical requirements. The company’s logistics arm as well as its network of branches, will provide us with the opportunity to ensure access of our key medications to pharmacies as well as hospitals, and ultimately, serve patients in a consistent and efficient manner.”

-END-

About Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.